Global Acquired Orphan Blood Diseases Therapeutics Market to Reach US$ 17.2 Billion by 2032, Catalyzed by Rapid Advancements in Medical Research

October 12, 2023 | Healthcare

According to the latest report by IMARC Group, titled “Acquired Orphan Blood Diseases Therapeutics Market Report by Therapy (Recombinant Factor, Immunoglobulin Infusion Therapy, Activated Prothrombin Complex Concentrate, Thrombopoietin Receptor Agonists, and Others), Disease Indication (Acquired Agranulocytosis, Acquired Hemophilia, Acquired Von Willebrand Syndrome, Paroxysmal Nocturnal Hemoglobinuria (PNH), Myelodysplastic Syndrome, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Others), and Region 2024-2032,” the global acquired orphan blood diseases therapeutics market size reached US$ 8.8 Billion in 2023. Acquired orphan blood disease therapeutics refers to the specialized medical treatments designed for rare blood disorders that are developed post-birth. They include a range of treatment modalities, such as targeted therapies, biologics, small molecule inhibitors, and gene therapies. Acquired orphan blood disease therapeutics are engineered to combat specific aspects of the disorder by utilizing complex biological components, proteins, or synthetic molecules. They are employed in hospitals, specialized treatment centers, and research institutions. Acquired orphan blood disease therapeutics offer numerous benefits, including early intervention, personalized treatment plans, improved patient quality of life, minimized disease progression, and curative possibilities. Additionally, they offer reduced side effects, targeted drug delivery, quicker recovery, cost-effectiveness in long-term disease management, and an increased treatment success rate.


Global Acquired Orphan Blood Diseases Therapeutics Market Trends:

The rapid advancements in medical research contributing to the identification and development of effective and targeted treatments for acquired orphan blood diseases, are major factors propelling the market growth. Moreover, the implementation of government policies and incentives, such as exclusive marketing rights and tax credits that encourage pharmaceutical companies to invest in research and innovation initiatives, is supporting the market growth. Along with this, the growing awareness and advocacy efforts by patient organizations and healthcare providers to educate the public and policy-makers about the critical need for treatment is stimulating the market growth. Besides this, rapid advances in genomic and proteomic technologies leading to the precise identification of disease etiologies are anticipated to drive the market growth. Furthermore, the rising partnerships and collaborations among research institutions, pharmaceutical companies, and healthcare providers for sharing knowledge, resources, and financial risks that accelerate the development and distribution of therapeutics are bolstering the market growth. In addition to this, the increasing establishment of specialized healthcare facilities and the availability of skilled professionals that serve to decentralize treatment, making it more accessible to a broader patient base, is acting as a growth-inducing factor. Apart from this, the rising prevalence of personalized medicine and the growing focus on patient-centric care models are also favoring the market growth. In line with this, the sudden shift towards value-based healthcare that impacts reimbursement policies, making it financially viable for healthcare providers and patients to opt for advanced treatment options, is creating remunerative growth opportunities for the market. Looking forward, the market value is projected to reach US$ 17.2 Billion by 2032, expanding at a CAGR of 7.5% during 2024-2032.


Market Summary:

  • Based on the therapy, the market has been divided into recombinant factor, immunoglobulin infusion therapy, activated prothrombin complex concentrate, thrombopoietin receptor agonists, and others.
  • On the basis of the disease indication, the market has been classified into acquired agranulocytosis, acquired hemophilia, acquired von willebrand syndrome, paroxysmal nocturnal hemoglobinuria (PNH), myelodysplastic syndrome, and others. According to the report, acquired hemophilia accounted for the largest market share.
  • Based on the distribution channel, the market has been categorized into hospital pharmacy, retail pharmacy, and others. Amongst these, hospital pharmacy accounted for the largest market share.
  • Region-wise, the market has been segmented into North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for acquired orphan blood diseases therapeutics.
  • The competitive landscape of the market has also been examined, with some of the key players being Alexion Pharmaceuticals Inc. (AstraZeneca plc), Amgen Inc., GSK plc, Novartis AG, Novo Nordisk A/S, Otsuka Pharmaceutical Co. Ltd., Rigel Pharmaceuticals Inc., Roche Holding AG, Sanofi, Takeda Pharmaceutical Company Limited, etc.


Report Scope:

Report Features Details
Base Year of the Analysis 2023
Historical Period 2018-2023
Forecast Period 2024-2032
Units US$ Billion
Scope of the Report Exploration of Historical and Forecast Trends, Industry Catalysts and Challenges, Segment-Wise Historical and Predictive Market Assessment: 
  • Therapy
  • Disease Indication
  • Distribution Channel
  • Region
Therapies Covered Recombinant Factor, Immunoglobulin Infusion Therapy, Activated Prothrombin Complex Concentrate, Thrombopoietin Receptor Agonists, Others
Disease Indications Covered Acquired Agranulocytosis, Acquired Hemophilia, Acquired Von Willebrand Syndrome, Paroxysmal Nocturnal Hemoglobinuria (PNH), Myelodysplastic Syndrome, Others
Distribution Channels Covered Hospital Pharmacy, Retail Pharmacy, Others
Regions Covered  Asia Pacific, Europe, North America, Latin America, Middle East and Africa
Countries Covered United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
Companies Covered Alexion Pharmaceuticals Inc. (AstraZeneca plc), Amgen Inc., GSK plc, Novartis AG, Novo Nordisk A/S, Otsuka Pharmaceutical Co. Ltd., Rigel Pharmaceuticals Inc., Roche Holding AG, Sanofi, Takeda Pharmaceutical Company Limited, etc.
Customization Scope 10% Free Customization
Report Price and Purchase Option Single User License: US$ 3899
Five User License: US$ 4899
Corporate License: US$ 5899
Post-Sale Analyst Support 10-12 Weeks
Delivery Format PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)


About Us:

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.


Contact Us:

IMARC Group
134 N 4th St.
Brooklyn, NY 11249, USA
Email: Sales@imarcgroup.com
Americas:- +1 631 791 1145 | Africa and Europe :- +44-753-713-2163 | Asia: +91-120-433-0800

Need more help?

  • Speak to our experienced analysts for insights on the current market scenarios.
  • Include additional segments and countries to customize the report as per your requirement.
  • Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  • For further assistance, please connect with our analysts.
Global Acquired Orphan Blood Diseases Therapeutics Market to Reach US$ 17.2 Billion by 2032, Catalyzed by Rapid Advancements in Medical Research
Purchase options




Benefits of Customization

Personalize this research

Triangulate with your data

Get data as per your format and definition

Gain a deeper dive into a specific application, geography, customer, or competitor

Any level of personalization

Get in Touch With Us
UNITED STATES

Phone: +1-631-791-1145

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-714-6104

Email: sales@imarcgroup.com

Client Testimonials

Aktive Services

IMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.

Read More
Greenfish S.A.

The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required

Read More
Colruyt Group

We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra

Read More
KRISHAK BHARTI CO-OP LTD

Last project executed by your team was as per our expectations. We also would like to associate for more assignments this year. Kudos to your team.

Read More
Zee Media Corp. Ltd.

We would be happy to reach out to IMARC again, if we need Market Research/Consulting/Consumer Research or any associated service. Overall experience was good, and the data points were quite helpful.

Read More
Arabian Plastic Manufacturing Company Ltd.

The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.

Read More
Sumitomo Corporation

The overall cost of the services were within our expectations. I was happy to have good communications in a timely manner. It was a great and quick way to have the information I needed.

Read More
Hameln Rds

My questions and concerns were answered in a satisfied way. The costs of the services were within our expectations. My overall experience with the IMARC Team was very good.

Read More
Quality Consultants BV

I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.

Read More
TATA Advanced Systems Limited

We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.

Read More
Stax

IMARC was a good solution for the data points that we really needed and couldn't find elsewhere. The team was easy to work, quick to respond, and flexible to our customization requests.

Read More